Cancers, Vol. 11, Pages 1223: Novel Biomarkers for Personalized Cancer Immunotherapy
Cancers, Vol. 11, Pages 1223: Novel Biomarkers for Personalized Cancer Immunotherapy
Cancers doi: 10.3390/cancers11091223
Authors:
Yoshitaro Shindo
Shoichi Hazama
Ryouichi Tsunedomi
Nobuaki Suzuki
Hiroaki Nagano
Cancer immunotherapy has emerged as a novel and effective treatment strategy for several types of cancer. Immune checkpoint inhibitors (ICIs) have recently demonstrated impressive clinical benefit in some advanced cancers. Nonetheless, in the majority of patients, the successful use of ICIs is limited by a low response rate, high treatment cost, and treatment-related toxicity. Therefore, it is necessary to identify predictive and prognostic biomarkers to select the patients who are most likely to benefit from, and respond well to, these therapies. In this review, we summarize the evidence for candidate biomarkers of response to cancer immunotherapy.
Source: Cancers - Category: Cancer & Oncology Authors: Yoshitaro Shindo Shoichi Hazama Ryouichi Tsunedomi Nobuaki Suzuki Hiroaki Nagano Tags: Review Source Type: research